Loading
A phase 1/2 trial of TH9619 in colorectal cancer, head and neck squamous cell carcinoma, non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by One-carbon Therapeutics AB, now recruiting.
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07151040 by One-carbon Therapeutics AB, with 43 participants planned, started 2025-08-22 and due to reach its primary completion in 2026-12. Interventions recorded: TH9619.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/